Baxter Int'l (NYSE: BAX) announced positive results from its Phase 3 pivotal ... treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis .. ...

64 people liked this